Search clinical trials for: HLX10 3mg/kg

Total 13429 results

Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Hepatocellular Carcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Hangzhou Grand Biologic Pharmaceutical, Inc.
Peking Union Medical College Hospital

Unknown

Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects

Healthy Participants

China
Johns Hopkins University
Cultivate Biologics

Completed

The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

Cannabis

United States
International AIDS Vaccine Initiative
Beth Israel Deaconess Medical Center; Ragon Institute of MGH, MIT and Harvard; University of Texas Health, Houston AIDS Research Team (HART) and other collaborators

Completed

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

HIV Infections

United States
Shanghai Henlius Biotech

Recruiting

A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Squamous Non-small-cell Lung Cancer

China
Xentria, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

Healthy Participants

United States
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Terminated

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Relapsed Lymphoid Malignancies | Refractory Lymphoid Malignancies

Australia
International AIDS Vaccine Initiative
Beth Israel Deaconess Medical Center, Boston MA; Ragon Institute of MGH, MIT... and other collaborators

Completed

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

HIV Infection

United States
GlaxoSmithKline

Completed

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) (DMD114876)

Muscular Dystrophies

United States
Genor Biopharma Co., Ltd.

Recruiting

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

HER2-positive Breast Cancer

China
GlaxoSmithKline

Completed

A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

Asthma

Germany, South Africa, Bulgaria
Shandong University

Recruiting

Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer

Cervical Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (GB226)

Lymphoma | Advanced Solid Tumor | Recurrent Solid Tumor | Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

China
Zhejiang Cancer Hospital

Recruiting

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

Extensive Stage Lung Small Cell Cancer

China
Amgen

Withdrawn

AMG 745 in Subjects With Age-associated Muscle Loss

Age-associated Muscle Loss
Martin Andreas, M.D.
National Bank of Austria; Orphan Medical

Completed

The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart

Myocardial Ischemia

Austria
Beijing VDJBio Co., LTD.

Completed

Clinical Study of Single Dose IL-6R mAb Injection in RA Patients

Rheumatoid Arthritis

China
Shanghai Henlius Biotech

Recruiting

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Non Small Cell Lung Cancer

China
Shanghai Henlius Biotech

Unknown

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

Solid Tumor

China
GeNeuro Innovation SAS

Terminated

A Long-term Extension of Study GNC-401

Multiple Sclerosis

Sweden
Seoul National University Hospital
Ministry of Food and Drug Safety, Korea

Completed

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children

Anesthesia, General | Neuromuscular Blockade

Korea, Republic of
Seoul National University Hospital
Ministry of Food and Drug Safety, Korea

Completed

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children

Anesthesia, General | Neuromuscular Blockade

Korea, Republic of
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Michael B. Atkins, MD
Bristol-Myers Squibb; Hoosier Cancer Research Network

Active, not recruiting

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
RenJi Hospital
Shanghai Zhongshan Hospital

Not yet recruiting

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

First-line Treatment of Non-clear Renal Cell Carcinoma
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Influenza

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Influenza

United States
Providence Health & Services

Completed

α-TEA in Advanced Cancer

Metastatic Sarcoma | Metastatic Carcinoma | Metastatic Lymphoma

United States
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Advanced Hepatocellular Carcinoma

China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Eisai Inc.
Biogen

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
Huahui Health

Terminated

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

Chronic Hepatitis B and Hepatitis D Co-infection

China
BioMarin Pharmaceutical

Terminated

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, Netherlands, France, United Kingdom, Italy
Shanghai Henlius Biotech

Not yet recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

CRC
National Cancer Institute (NCI)

Recruiting

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Malignant Glioma | Gliosarcoma

United States

3

Subscribe